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Abstract
Background: The low-density lipoprotein receptor-related protein 5 gene (LRP5) was identified
to be linked to the variation in BMD in high bone mass pedigrees. Subsequent population-based
studies of the association between the LRP5 gene and BMD have yielded conflicting results. The
present study was aimed at examining the association between LRP5 gene and BMD by using meta-
analysis.
Methods: A systematic electronic search of literature was conducted to identify all published
studies in English on the association between LRP5 gene and osteoporosis-related phenotypes,
including bone mineral density and fracture. BMD data were summarized from individual studies by
LRP5 genotype, and a synthesis of data was performed with random-effects meta-analyses. After
excluding studies on animal and review papers, there were 19 studies for the synthesis. Among
these studies, 10 studies used the rs3736228 (A1330V) polymorphism and reported BMD values.
Results: The 10 eligible studies comprised 16,705 individuals, with the majority being women (n =
8444), aged between 18 – 81 years. The overall distribution of genotype frequencies was: AA, 68%,
AV and VV, 32%. However, the genotype frequency varied significantly within as well as between
ethnic populations. On random-effects meta-analysis, lumbar spine BMD among individuals with the
AA genotype was on average 0.018 (95% confidence interval [CI]: 0.012 to 0.023) g/cm2 higher than
those with either AV or VV genotype. Similarly, femoral neck BMD among carriers of the AA
genotype was 0.011 (95%CI: 0.004 to 0.017) g/cm2 higher than those without the genotype. While
there was no significant heterogeneity in the association between the A1330V polymorphism and
lumbar spine BMD (p = 0.55), the association was heterogeneous for femoral neck BMD (p = 0.05).
The probability that the difference is greater than one standard deviation was 0.34 for femoral neck
BMD and 0.54 for lumbar spine BMD.
Conclusion: These results suggest that there is a modest effect of the A1330V polymorphism on
BMD in the general population, and that the modest association may limit its clinical use.
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Background
Bone mineral density (BMD) is a primary predictor of
osteoporotic fracture [1], and is used as a surrogate defini-
tion of osteoporosis [2]. Several epidemiological studies
have consistently demonstrated that each standard devia-
tion (SD) lowering in BMD is associated with an approxi-
mately 2-fold increase in fracture risk [3]. This strength of
association is equivalent to or even stronger than the asso-
ciation between serum cholesterol and cardiovascular
events [4], or between blood pressure measurements and
risk of stroke mortality [5]. BMD changes with age, with
peak levels been reached between the age of 20 and 30
and then decreasing during the later decades of life. Any
BMD level -2.5 standard deviations or more below the
young normal average level is classified as osteoporosis
[6].
Extensive evidence from twin studies and family-based
studies have suggested that between 60% and 82% vari-
ance of BMD is attributable to genetic factors [7,8]. Dur-
ing the past two decades, it has become clear that many
genes contribute to the variation in BMD in the general
population; however, the localization of specific genes
has not been always successful, due to on-going conflict-
ing and contradictory findings [9].
A linkage analysis of a pedigree from a proband with the
osteoporosis-pseudoglioma syndrome (OPS), a disorder
characterized by severely low bone mass and eye abnor-
mality, identified a locus on chromosome 11 linked to
variation in BMD in the pedigree [10]. The linkage
between the region and BMD was reported independently
from a genome-wide linkage analysis of an extended fam-
ily with 22 members among whom 12 had very high bone
mass [11]. In follow-up studies using the positional can-
didate approach both research groups found that the gene
encoding the low-density lipoprotein receptor-related
protein 5 (LRP5) was linked to both OPS and high bone
mass [12-14]. Six novel mutations in LRP5 among 13 con-
firmed polymorphisms have also been associated with
different conditions with increased BMD [15].
Since the identification of the LRP5 gene, several popula-
tion-based association studies have examined the associa-
tion between LRP5 polymorphisms and normal variation
in BMD [14,16-24]. However, these studies have yielded
contradictory results, with some studies showing a signif-
icant association, while others did not. Thus, the role of
LRP5 gene in the regulation of BMD in the general popu-
lation has not been clear. In the presence of inconsistent
findings, a systematic review by compiling all available
data and synthesizing them into a coherent summary may
provide a more reliable conclusion about the association
between LRP5 polymorphisms and BMD. The present
study was aimed at using the Bayesian approach to sum-
marize the overall effect of LRP polymorphisms on BMD
variation in different populations.
Methods
Literature search
A systematic search the literature was carried out by using
electronic databases including Pubmed, Ovid (from 2001
to March 2008), and the Cochrane Controlled Trials Reg-
istered from 1960 to March 2004. The language was lim-
ited to English. The keywords used for this search were
"LDL receptor-related protein 5 gene OR LRP5 gene" con-
catenated with "osteoporosis OR bone mineral density
OR bone density OR BMD", and "fracture*". Two review-
ers (BT and NN) identified eligible articles for which the
abstracts were recorded. Then, if the abstract was consist-
ent with the inclusion criteria, the full article text was
obtained. The inclusion criteria were (a) original papers;
(b) population-based association study with BMD being
the outcome; and (c) adult men or women (aged 18+
years). The exclusion criteria were: (a) animal studies; (c)
family studies; (c) review papers; and (d) studies on chil-
dren or adolescents.
The full texts of all potentially relevant papers were
obtained and three reviewers (BT, NN and TN) independ-
ently checked for data consistency. If more than one paper
with the same data was identified, only the one that con-
tained the original data were included. For studies in
which BMD measurements were not presented as mean
and SD for each genotype, we contacted the authors to
request the data using a formatted collection form. For
each study, relevant data including details of study design,
study duration, gender, BMD measurements, LRP5 poly-
morphisms, inclusion and exclusion criteria, and inci-
dence of fractures were extracted. As there have been very
few studies on an association between LRP5 polymor-
phism and fracture [16], the primary outcome in this
meta-analysis was BMD (Table 1).
Data synthesis and analysis
In each study, the outcome data (BMD) were extracted
and summarized by genotype. The effect size for each
study was the difference in BMD between genotypes
(denoted di). The aim was to estimate an overall effect or
weighted mean difference (WMD) in BMD between geno-
types (denoted by d). This was done by both traditional
(fixed-effects and random-effects models) meta-analysis
[25], which have been described elsewhere [26] and fully
Bayesian method [27,28]. Briefly, each di is assumed to be
normally distributed with a "true" but unknown effect
size θi and a within-study variance  . Furthermore, the
collection of di across studies is assumed to follow a nor-
mal distribution with unknown mean θ and variance τ2.
σ i
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Thus, θ is the overall WMD in BMD between genotypes
across studies and τ2 is the between-study variance. The
classical fixed-effects method of meta-analysis assumes
that τ2 = 0, whereas the classical random-effects method
recognizes the possibility of heterogeneity of study-to-
study variation (i.e., that τ2 could be difference from 0).
All parameters of the classical fixed and random-effects
model were estimated by the inverse variance weighting
method as implemented by the "meta" package within the
R language [29].
In contrast to the traditional random-effects model where
the parameters θ, σ2 and τ2 are assumed to be fixed, in
Bayesian random-effects model,   and τ2 are assumed
to be random variables. Furthermore, the Bayesian
approach allows incorporate the existing data into the
present analysis; therefore, the effect sizes of association
between LRP5 variants and bone mineral density from a
recent large-scale study were included in the analysis [30].
Fully Bayesian analysis refers to the use of external prior
information, which must be specified for θ and τ2 in the
estimation of the overall effect size. In this analysis, the
prior distribution for τ2 was assumed to be uniformly dis-
tributed with parameters (0, 10) to recognize the uncer-
tainty of effect sizes. The prior distribution for θ was given
as a normal distribution of mean 0 and variance of 10000
to reflect the fact that the knowledge of effect sizes was
vague. This is also considered a "referent prior", in the
sense that it reflects the equal effect of genotypes in BMD
variations. The estimation of model parameters was per-
formed by the MCMC technique with the WinBUGS pro-
gram [31].
The heterogeneity of effects across studies was assessed by
computing the Cochran's Q statistic [32] and the coeffi-
cient of inconsistency (I2), as described by Higgins et al
[33]. Funnel plots were performed to identify any possible
evidence of publication bias [34,35]. Finally, recursive
cumulative meta-analysis was also performed to examine
whether the magnitude of effect changes markedly with
sample size. In this analysis, each smaller size study was
considered as an informative step, in which evidence was
updated by larger sample size studies published in the
interim.
Results
Characteristics of studies
The electronic search yielded 65 papers on the association
between LRP5 and osteoporosis-related phenotypes; how-
ever, only 19 met the inclusion criteria (Figure 1). Among
the 22 SNPs used in various studies, the following 10
SNPs were more common (in order of the frequency of
studies): rs3736228, rs4988321, rs41494349, rs2277268,
rs2306862, rs556442, rs17149104, rs11574422,
rs545382, rs4988319. Fourteen studies examined the
association between the SNP rs3736228 (A1330V poly-
morphism, alanine-to-valine substitution at position
1330 in exon 18) within the LRP5 gene and BMD or frac-
ture in human. Among the 14 studies, 8 papers reported
actual BMD data by genotype. Corresponding authors of
the 6 remaining papers were contacted with a data collec-
tion form, however, only 2 responded. The three studies
that were not included in this analysis found no signifi-
σ i
2
Table 1: Characteristics of individual studies
Study Study 
design
Ethnicity Age 
(mean or range)
BMD 
measurement
Sex Frequency of A1330V genotypes Frequency of 
AA
AA AV VV
Koh, 2004 [23] CS Asian 25.6 LS + FN Men 161 51 7 0.74
Mizuguchi, 2004 [37] CC Asian 54.2 LS Women 129 114 11 0.51
Koller, 2005 [24] CS Caucasian 20 – 50 LS + FN Women 833 416 52 0.64
Zhang, 2005 [38] C Asian 60.1 LS + FN Women 440 192 15 0.68
van Meurs, 2006 [39] C Caucasian ≥ 55 LS + FN Mena 895 643 54 0.56
Caucasian Women 2766 939 76 0.73
Ezura, 2007 [18] CS Asian 64.6 LS Women 178 174 35 0.46
Saarinen, 2007 [40] CS Caucasian 18 – 21 LS + FN Men 215 20 0.91
Giroux, 2007 [20] CS Caucasian 53.3 LS + FN Women 1452 622 0.70
Grundberg, 2007 
[21]
CS Caucasian 69 – 81 LS + FN Men 2114 620 33 0.76
CS Asian > 65 LS + FN Men 1067 487 70 0.66
CS Caucasian 18 – 20 LS + FN Men 806 216 23 0.77
Brixen, 2007 [36] CS Caucasian 20 – 30 LS Men 589 170 20 0.76
CS = cross-sectional study, CC = case-control study, C = cohort study; LS = lumbar spine, FN = femoral neck.
aThe distribution of genotypes was not consistent with the Hardy-Weinberg's equilibrium law (p < 0.0001).BMC Medical Genetics 2008, 9:55 http://www.biomedcentral.com/1471-2350/9/55
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cant association between the SNP rs3736228 (referred as
SNP A1330V in the article) and BMD. Eventually, data
from 10 studies [18,20,21,23,24,36-40] were included in
the traditional analysis of association with BMD. In a
recent large-scale analysis of the association between
LRP5 polymorphisms and BMD or fracture in Caucasian
individuals, the results were only shown effect sizes of the
association [30]; therefore, this study was only able to be
incorporated in the Bayesian approach.
Five studies were conducted on Asian populations (i.e.,
Chinese, Japanese, and Korean) [18,21,23,24,37,38],
with a total sample size of 3131 individuals and 6 studies
were on Caucasian populations with 13,574 individuals
[20,21,24,36,39,40]. Approximately 80% of participants
were women. The average age of all participants was 60
years (range: 18 to 81 years).
Distribution of LRP5 genotypes
There was high variability in the genotypic distribution
within and between populations. For example, within the
Asian populations, the relative frequency of the A1330V
AA genotype ranged between 46% in Japanese women
[18] to 68% in Chinese women [38] and 64% in Cauca-
sian women [24]. However, in a study among Korean
men, the frequency of AA genotype was 74% [23]. In Cau-
casian populations, the A1330V AA genotype was found
in 56% of Dutch men [39], which was significantly lower
than that in Finnish men 91% [40] (Table 2). The fre-
quency of AA genotype in Swedish men was around 76%
[21].
Summary of search strategy and result Figure 1
Summary of search strategy and result.
Initial search for related papers: 65 
papers retrieved 
19 papers met criteria 
14 studies were related to LRP5 
A1330V polymorphism 
10 studies with BMD data 
available for extraction
Exclude those papers with: 
-  Basic research: 12 
-  Animal study: 4 
-  Review paper: 3 
-  Not related to BMD or 
osteoporosis: 19 
-  Familial study: 7 
-  Children: 1 
Exclude those studies without 
A1330V polymorphism 
studies 
Exclude those studies which 
authors could not be 
contacted or data were not 
available. BMC Medical Genetics 2008, 9:55 http://www.biomedcentral.com/1471-2350/9/55
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Women of Caucasian background appeared to have sig-
nificantly higher relative frequency of the AA genotype
than their Asian counterparts (70% vs. 55%)
[18,20,24,37-39]; however, the observation was not
found in men (75% vs. 70%).
Association between LRP5 genotypes and BMD
As genotype VV was low in most populations (i.e., approx-
imately 3.4%), data from the VV and AV genotypes were
combined into one group which was then compared to
the AA genotype. This approach of combination was also
utilized in most primary studies.
Pooled effect size
Classical meta-analysis
In classical random-effects model, femoral neck BMD in
individuals with genotype AA was significantly higher
than in those with the AV and VV genotypes combined
(WMD: 0.011, 95% CI: 0.004 to 0.017 g/cm2) (Table 3).
Lumbar spine BMD in individuals homozygous for allele
A was on average 0.018 g/cm2 (95% CI: 0.012 to 0.023 g/
cm2) higher than that in individuals with allele V (AV and
VV genotypes combined) (Figure 2 and 3). For both sites,
fixed-effects and random-effects analyses were almost
identical.
The cumulative meta-analysis showed that after a cumula-
tive sample size of 15,285 individuals for femoral neck
and 16,705 for lumbar spine, the association between
A1330V variant and BMD became statistically apparent
(Figure 4).
Bayesian meta-analysis
In Bayesian analysis, we analyzed two models separately:
model I and model II. Model I included the data used for
the "classical" analysis and in model II, we incorporated
the data used for the "classical" analysis with recently pub-
lished data [30]. The difference in results of two models
was modest (data not shown); therefore, the results of
model II were presented. Parameters obtained from Baye-
Table 2: Summary of BMD data by A1330V genotype
First author, year Gender Femoral neck BMD Lumbar spine BMD
AA AV/VV AA AV/VV
Koh, 2004 [23] Men 1.07 (0.15) 1.03 (0.15) 1.20 (0.18) 1.21 (0.13)
Mizuguchi, 2004 [37] Women - - 0.81 (0.16) 0.78 (0.16)
Koller, 2005 [24] Women 1.01 (0.12) 0.99 (0.11) 1.29 (0.13) 1.27 (0.12)
Zhang, 2005 [38] Women 0.66 (0.12) 0.65 (0.11) 0.80 (0.14) 0.79 (0.14)
van Meurs, 2006 [39] Men 0.92 (0.12) 0.91 (0.12) 1.17 (0.20) 1.14 (0.19)
Women 0.83 (0.14) 0.83 (0.14) 1.04 (0.19) 1.02 (0.19)
Ezura, 2007 [18] Women - - 0.91 (0.22) 0.88 (0.19)
Saarinen, 2007 [40] Men 1.18 (0.15) 1.09 (0.14) 1.23 (0.13) 1.18 (0.14)
Giroux, 2007 [20] Women 0.88 (0.14) 0.87 (0.14) 1.12 (0.17) 1.10 (0.17)
Grundberg, 2007 [21] Men 0.83 (0.13) 0.82 (0.13) 1.14 (0.20) 1.14 (0.20)
Men 0.69 (0.11) 0.69 (0.12) 0.95 (0.17) 0.94 (0.18)
Men 1.16 (0.15) 1.17 (0.17) 1.24 (0.15) 1.22 (0.14)
Brixen, 2007 [36] Men - - 1.08 (0.12) 1.07 (0.17)
Values are mean (standard deviation).
Table 3: Sub-group analysis by sex and ethnicity (random-effects model)
Subgroup Femoral neck BMD Lumbar spine BMD
WMD (95% CI) P value I2 (%) WMD (95% CI) P value I2 (%)
Overall 0.011 (0.004, 0.017) 0.002 46.8 (p = 0.05) 0.018 (0.012, 0.023) <0.0001 0 (p = 0.55)
Ethnicity
Asian 0.011 (-0.006, 0.028) 0.21 51.3 (p = 0.13) 0.014 (0.002, 0.027) 0.02 0 (p = 0.62)
Caucasian 0.011 (0.003, 0.019) 0.01 52.1 (p = 0.05) 0.018 (0.012, 0.025) <0.0001 10.5 (p = 0.35)
Gender
Men 0.011 (0.0004, 0.022) 0.04 50.6 (0.07) 0.014 (0.003, 0.025) 0.01 32.8 (p = 0.18)
Women 0.011 (0.001, 0.021) 0.03 55.8 (0.08) 0.020 (0.013, 0.028) <0.0001 0 (p = 0.98)
WMD, weighted mean difference in BMD between AA and AV/VV genotypes
I2, inconsistent indexBMC Medical Genetics 2008, 9:55 http://www.biomedcentral.com/1471-2350/9/55
Page 6 of 13
(page number not for citation purposes)
sian meta-analysis were used to estimate posterior distri-
butions of mean difference in BMD between AA and AV/
VV genotypes (Figure 5a and 5b). The area under the curve
between any two points on the distribution is an estimate
of the probability of effect size. For example, shaded areas
in figures 5a and 5b represent for the probability that the
effect size (AA vs. AV/VV) of >0.1 SD of FNBMD and
LSBMD by using random-effects model, respectively (each
SD was 0.12 g/cm2for FNBMD and 0.17 g/cm2  for
LSBMD). These areas accounted for ~34% of the whole
area under the curve for femoral neck BMD and ~54% for
lumbar spine BMD. In other words, the probability that
the effect size (AA vs. AV/VV) of >0.1 SD was ~34% for
FNBMD and ~54% for LSBMD. There was a 100% chance
that the effect size was less than 0.25 SD. In other words,
the probability for a possible difference in BMD between
genotypes at both the femoral neck and lumbar spine was
highly likely lower than 0.25 SD.
Subgroup analysis
In subgroup analyses, the effect of A1330V variant on
BMD was found to be present in Asian populations at the
lumbar spine (WMD between AA and AV/VV: 0.014; 95%
CI: 0.002 to 0.027 g/cm2) and in Caucasian populations
at either the lumbar spine (WMD: 0.018; 95% CI: 0.012
to 0.025 g/cm2) or at femoral neck (WMD: 0.011, 95% CI:
0.003 to 0.019 g/cm2) (Table 3). Analysis by sex revealed
that the association between the A1330V variant and
BMD was significant in both genders, with WMD for
women being 0.02 (95% CI: 0.013 to 0.028 g/cm2) for
lumbar spine and 0.011 (95% CI: 0.001 to 0.021 g/cm2)
for femoral neck (Table 3). In men, WMD in BMD
Weighted mean difference and 95% confidence interval in femoral neck BMD between AA and AV/VV genotypes Figure 2
Weighted mean difference and 95% confidence interval in femoral neck BMD between AA and AV/VV geno-
types. The size of plots was proportional to their sample size. Each study was shown difference of BMD in men (M) and 
women (W) using random effects model. The diamond showed the overall effect of the association. Reduced BMD was shown 
in group of AV/VV genotype compared to AA genotype when the diamond was set toward the right of the vertical line.
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between AA and AV/VV were 0.014 (95% CI: 0.003 to
0.025 g/cm2) for lumbar spine and 0.011 (95% CI:
0.0004 to 0.022 g/cm2) for femoral neck (Table 3).
Assessment of heterogeneity and publication bias
There was no evidence of heterogeneity in lumbar spine
BMD (I2 = 0, p = 0.55). However, the effects of the A1330V
variant on femoral neck BMD were significantly different
among studies, with the coefficient of inconsistency being
46.8% (p = 0.05) (Table 3).
In the funnel plot (Figure 6), there was symmetry in lum-
bar spine BMD (p = 0.65), suggesting no significant pub-
lication bias. However, the asymmetric feature in femoral
neck BMD showed a trend of publication bias (p = 0.02).
Nevertheless, when the analysis was limited to women
only, there was no evidence of publication bias in either
lumbar spine (p = 0.35) and femoral neck BMD (p =
0.17).
Discussion
The discovery of linkage between the LRP5 gene and high
bone mass was considered a genuine progress in the
genetics of osteoporosis, a disorder that has been known
to have a substantial genetic component. However, since
linkage can only demonstrate a correlated transmission of
alleles within pedigrees, the relative contribution of the
LRP5 gene to BMD in population has to be assessed in
association studies. Several association studies have tested
the association between the LRP5 gene and BMD, but the
results were inconsistent, with different polymorphisms
being used and different study designs and sample sizes.
In the present meta-analysis, by systematically combining
all previous studies, there was a significant association
between the A1330V polymorphism and lumbar spine
Weighted mean difference and 95% confidence interval in lumbar spine BMD between AA and AV/VV genotypes Figure 3
Weighted mean difference and 95% confidence interval in lumbar spine BMD between AA and AV/VV geno-
types. Explanations were presented in figure 2.
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BMD in both Asian and Caucasian populations. However,
that variation at the A1330V polymorphism explained
about 0.2 to 0.5% of between-subjects variation in BMD,
which suggested that the effect of this LRP5 gene polymor-
phism on BMD was modest.
The present meta-analysis also suggests that the magni-
tude of effect of the A1330V on BMD was similar in both
men and women, which was consistent with previous
observations (Table 3) [17,39]. Similarly, the statistically
significant association between A1330V and BMD at both
sites was observed in Caucasian populations, but the asso-
ciation only found in Asian populations, which was likely
due to the large sample size of the former populations.
It is interesting to observe that although the genotypic dis-
tribution was consistent with the Hardy-Weinberg's equi-
librium law in most studies, the relative distribution of
the A1330V genotypes varied remarkably between – as
well as within-populations. For example, the AA genotype
was 68% in Chinese women [38], 46% in Japanese
women [18], or 73% of in Dutch women [39]. Among
Caucasian populations, the AA genotype was detected in
56% in Dutch men [39] vs. 91% in Finnish men [40], and
76% in Danish men [36]. It is not clear why there was
such a major difference in the genotypic distributions;
however, population stratification and/or mixed ethnici-
ties could be the underlying responsible factors. Gender
and ethnicity may both interact to the influence of LRP5
polymorphism in association to BMD [41].
These analyses suggested that the clinical use of this gene
variant was may be limited due to its modest effect size on
BMD. The average difference in BMD between those
homozygous for allele A and those with V allele was
approximately 0.1 SD. Each SD lower BMD was associated
with an approximately two-fold in fracture risk [1]. There-
fore, it seems that the AA genotype within the A1330V
polymorphism confers minimal protection against frac-
ture via increased BMD. However, it is possible that the
variant can have positive effect on fracture independent of
BMD, and its use in conjunction with BMD and other clin-
ical factors may identify a subset of high-risk individuals
of fracture.
The magnitude of association between LRP5 polymor-
phism and BMD in this study was lower than that of
between Collagen I alpha 1 gene (COLIA1) and BMD. In
a previous meta-analysis, the difference between two
homozygous genotypes of the COLIA1 gene was approxi-
mately 1 SD for femoral neck BMD (0.19 g/cm2, 95% CI
0.07 to 0.31), but not for lumbar spine BMD (0.09 g/cm2,
95% CI -0.03 to 0.21) [42]. On the other hand, a number
of meta-analyses on the association between the vitamin
D receptor gene (VDR) and BMD revealed an effect size of
less than 0.1 SD [43,44].
Cumulative meta-analysis (by sample size) for femoral neck (left panel) and lumbar spine BMD (right panel) Figure 4
Cumulative meta-analysis (by sample size) for femoral neck (left panel) and lumbar spine BMD (right panel). In 
each additional study, the mean difference (95% CI) of BMD difference between AA and AV/VV genotypes were computed 
accumulatively.
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A recent genome-wide association study between LRP5
polymorphisms and BMD or fracture in a large scale [45]
found the A1330V polymorphism was associated with
BMD at the lumbar spine and femoral neck, in which the
risk allele V was associated with a 0.13 SD decrease in
BMD, and accounted for 0.6% and 0.2% of the variation
in lumbar spine and femoral neck BMD, respectively.
Taken together, these results suggest that although there
was a "true" association between the A1330V polymor-
phism and BMD, the effect is likely to be modest because
Posterior distribution of weighted mean difference (WMD) in BMD at the femoral neck (A) and lumbar spine (B) Figure 5
Posterior distribution of weighted mean difference (WMD) in BMD at the femoral neck (A) and lumbar spine 
(B). For example, shaded areas in the figures represent for the probability that the effect size (AA vs. AV/VV) of >0.1 SD of 
FNBMD and LSBMD by using random-effects model, respectively. These areas accounted for ~34% of the whole area under 
the curve for femoral neck BMD and ~54% for lumbar spine BMD. In other words, the probability that the effect size (AA vs. 
AV/VV) of >0.1 SD was ~34% for FNBMD and ~54% for LSBMD. Results from fixed-effects and random-effects analysis were 
almost identical for LSBMD. FNBMD, femoral neck bone mineral density; LSBMD; lumbar spine bone mineral density; 1 SD was 
0.12 g/cm2 for BMD at the femoral neck and 0.17 g/cm2 at the lumbar spine.
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the gene variant explained less than 1% of the variation in
BMD.
The modest effect of the LRP5 gene on BMD is consistent
with the view that the disorder is affected by several genes,
each with small effect size [46]. Indeed, more than 50
genes have been proposed or identified to be associated
with either BMD or fracture risk [47,48]; however, apart
from the COLIA1, none of those genes have been conclu-
sively demonstrated to have major effect on any oste-
oporosis-related phenotypes. The present meta-analysis
suggested that the identification of specific genes that
truly affect BMD can be a daunting task, because of a reli-
able result (i.e., low false positive rate), a typical associa-
tion study requires at least 6600 individuals.
It is possible that the main effect of the LRP5 gene on
BMD is modest, but it is also equally possible that the
gene may confer a greater effect when it interacts with an
environmental exposure or with other genes. However,
these possibilities of gene-environment or gene-gene
interactions have not been systematically explored in the
field of osteoporosis. As a result, the present analysis can
not address the issue of gene-environment or gene-gene
interactions.
Although the present analysis supported an association
between the LRP5 gene and BMD, the result must be con-
sidered in terms of a number of strengths and caveats.
One strength of meta-analysis is that it increases the
power for defining a fine association that is not usually
possible in small individual studies. Nevertheless, given
the weak association observed here, the possibility of false
positive finding (or, for that matter, false negative find-
ing) can not be ruled out, particularly in relation to the
association found in men. Moreover, as with any meta-
analysis, exclusion of pertinent unpublished studies is
always a "threat" to the validity of the analysis.
The use of the Bayesian approach in this analysis deserves
a mention. Tradition meta-analysis can estimate an effect
size, but it is not possible to make a probabilistic state-
ment about the effect size. In contrast, by treating the
effect size as a random variable, Bayesian analysis can
make inference on various probable effect sizes. Indeed,
by combining a prior distribution with observed data
from primary studies within the Bayesian theorem it is
possible to make such an inference [47-49]. Thus, the
Bayesian approach allows us to directly address the clini-
cal question of "given the observed data, what is the prob-
ability of the 'true' difference in BMD between
genotypes". This is different from the classical statistical
approach in which the interpretation is entirely depend-
ent on the p-value. The p-value is the probability that the
test statistic is "significant" given that there is no differ-
ence in BMD between genotypes. This p-value based infer-
Funnel plot of weighted mean difference for femoral neck BMD (p = 0.02) and for lumbar spine BMD (p = 0.65) versus inverse  standard error Studies with higher effect size tended to have larger standard error Figure 6
Funnel plot of weighted mean difference for femoral neck BMD (p = 0.02) and for lumbar spine BMD (p = 0.65) 
versus inverse standard error Studies with higher effect size tended to have larger standard error. (1 SD was 
estimated of 0.12 g/cm2 and 0.15 g/cm2 for femoral neck and lumbar spine, respectively).
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ence has been charged as counter-intuitive and even "false
reasoning" [50]. In other words, classical statistical infer-
ence is concerned with the probabilistic behavior of a test
statistic, whereas Bayesian inference is concerned with the
research question. Moreover, In Bayesian analysis, one is
not limited to consider the present data, but must take
into account any data that have been previously been
known. By using the Bayesian approach, we have shown
that the difference in BMD between AA and AV/VV geno-
types is less than 0.25 SD; there was virtually no chance
that the effect size is greater than 0.25 SD.
In this analysis, there is no evidence of publication bias
for the association between lumbar BMD and LRP5 gene.
Although the best attempt has been made to search all rel-
evant published studies, it is impossible to know how
many "negative studies" are unpublished. Of the 14 eligi-
ble studies, it was only possible to retrieve analyzable data
from 10 studies despite many efforts. The remaining 4
studies reported a non-significant association between the
A1330V polymorphism and BMD [17,19,41,51]. There-
fore, it could be argued that results of the present study
may overestimate the true effect of LRP5 gene on BMD.
It should be noted that the present analysis was limited to
a single SNP (rs3736228) within the LRP5 gene. Although
this SNP has been used in most studies, other SNPs have
also been shown to be associated with BMD. In recent
years, the analysis of genetic association has shifted from
the single SNP-based analysis to a more reductionistic
approach such as SNP-based haplotypes. Some studies
found no association between the LRP5 gene and BMD
when analyzing each SNP as a separate variable, but were
able to detect an association when the analysis was based
on the use of SNP-based haplotypes [17,41]. The present
meta-analysis did not consider the haplotype association;
therefore, the estimate does not reflect any more complex
association between the LRP5 gene and BMD. However,
haplotype analyses reported in primary studies also
showed that the magnitude of association between the
gene and BMD is modest, with variation among haplo-
types accounting for between 0.5 and 1.2% of the varia-
tion in BMD [22,52,53].
Thus, irrespective of the haplotype or single SNP-based
analysis, results of this meta-analysis indicated that the
A1330V variant within the LRP5 gene is modestly associ-
ated with bone mineral density, and that the modest effect
size may limit its use in clinical setting.
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